WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H333090
CAS#: 1041434-82-5 (hydrate)
Description: Peramivir, also known as BCX1812 and RWJ 270201, is an antiviral drug for the treatment of influenza. Peramivir is a neuraminidase inhibitor, acting as a transition-state analogue inhibitor of influenza neuraminidase and thereby preventing new viruses from emerging from infected cells. Peramivir was approved to treat influenza infection in adults.
Hodoodo Cat#: H333090
Name: Peramivir hydrate
CAS#: 1041434-82-5 (hydrate)
Chemical Formula: C15H34N4O7
Exact Mass: 0.00
Molecular Weight: 382.460
Elemental Analysis: C, 47.11; H, 8.96; N, 14.65; O, 29.28
Related CAS #: 330600-85-6 (free) 1041434-82-5 (hydrate)
Synonym: RWJ 270201 trihydrate; BCX 1812 trihydrate; RWJ 270201 hydrate; BCX 1812 hydrate
IUPAC/Chemical Name: (1S,2S,3R,4R)-3-((S)-1-acetamido-2-ethylbutyl)-4-guanidino-2-hydroxycyclopentanecarboxylic acid trihydrate
InChi Key: RFUCJKFZFXNIGB-ZBBHRWOZSA-N
InChi Code: InChI=1S/C15H28N4O4.3H2O/c1-4-8(5-2)12(18-7(3)20)11-10(19-15(16)17)6-9(13(11)21)14(22)23;;;/h8-13,21H,4-6H2,1-3H3,(H,18,20)(H,22,23)(H4,16,17,19);3*1H2/t9-,10+,11+,12-,13+;;;/m0.../s1
SMILES Code: O=C([C@@H]1[C@@H](O)[C@@H]([C@@H](NC(C)=O)C(CC)CC)[C@H](NC(N)=N)C1)O.[H]O[H].[H]O[H].[H]O[H]
Appearance: To be determined
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: To be determined
Shelf Life: >2 years if stored properly
Drug Formulation: To be determined
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 382.46 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Xu M, Cai T, Yue T, Zhang P, Huang J, Liu Q, Wang Y, Luo R, Li Z, Luo L, Ji C, Tan X, Zheng Y, Whitley R, De Clercq E, Yin Q, Li G. Comparative Effectiveness of Oseltamivir versus Peramivir for Hospitalized Children (ages 0-5 years) with Influenza Infection. Int J Infect Dis. 2023 Jan 3:S1201-9712(22)00680-4. doi: 10.1016/j.ijid.2022.12.043. Epub ahead of print. PMID: 36608788.
2: Sarukhanyan E, Shanmugam TA, Dandekar T. In Silico Studies Reveal Peramivir and Zanamivir as an Optimal Drug Treatment Even If H7N9 Avian Type Influenza Virus Acquires Further Resistance. Molecules. 2022 Sep 12;27(18):5920. doi: 10.3390/molecules27185920. PMID: 36144655; PMCID: PMC9503969.
3: Zhang CX, Tu Y, Sun XC, Chen DG, Zhang WN, Zhuang CL, Wang ZB, Su L. Peramivir, an Anti-Influenza Virus Drug, Exhibits Potential Anti-Cytokine Storm Effects. Front Immunol. 2022 Feb 28;13:856327. doi: 10.3389/fimmu.2022.856327. PMID: 35296098; PMCID: PMC8918788.
4: Mtambo SE, Ugbaja SC, Kumalo HM. Impact of the R292K Mutation on Influenza A (H7N9) Virus Resistance towards Peramivir: A Molecular Dynamics Perspective. Molecules. 2022 Mar 2;27(5):1645. doi: 10.3390/molecules27051645. PMID: 35268746; PMCID: PMC8912059.
5: Mtambo SE, Ugbaja SC, Mushebenge AG, Abubakar BH, Ntuli ML, Kumalo HM. Intermolecular Mechanism and Dynamic Investigation of Avian Influenza H7N9 Virus' Susceptibility to E119V-Substituted Peramivir-Neuraminidase Complex. Molecules. 2022 Mar 2;27(5):1640. doi: 10.3390/molecules27051640. PMID: 35268741; PMCID: PMC8911867.
6: Cies JJ, Moore WS 2nd, Marino D, Deacon J, Enache A, Chopra A. Oxygenator impact on peramivir in extra-corporeal membrane oxygenation circuits. Perfusion. 2022 Feb 28:2676591211060975. doi: 10.1177/02676591211060975. Epub ahead of print. PMID: 35225084.
7: Kato M, Saisho Y, Tanaka H, Bando T. Improvement of respiratory symptoms and health-related quality of life with peramivir in influenza patients with chronic respiratory disease: Additional outcomes of a randomized, open-label study. Influenza Other Respir Viruses. 2021 Sep;15(5):651-660. doi: 10.1111/irv.12835. Epub 2021 Mar 8. PMID: 33683019; PMCID: PMC8404055.
8: Fang YH, Hsu TH, Lin TY, Liu CH, Chou SC, Wu JY, Perng PC. Comparing intravenous peramivir with oral oseltamivir for patients with influenza: a meta- analysis of randomized controlled trials. Expert Rev Anti Infect Ther. 2021 Aug;19(8):1039-1046. doi: 10.1080/14787210.2021.1878025. Epub 2021 Mar 1. PMID: 33641583.
9: Chen HD, Wang X, Yu SL, Ding YH, Wang ML, Wang JN. Clinical Effectiveness of Intravenous Peramivir Compared With Oseltamivir in Patients With Severe Influenza A With Primary Viral Pneumonia: A Randomized Controlled Study. Open Forum Infect Dis. 2020 Nov 18;8(1):ofaa562. doi: 10.1093/ofid/ofaa562. PMID: 33447633; PMCID: PMC7793458.
10: Twabela A, Okamatsu M, Matsuno K, Isoda N, Sakoda Y. Evaluation of Baloxavir Marboxil and Peramivir for the Treatment of High Pathogenicity Avian Influenza in Chickens. Viruses. 2020 Dec 8;12(12):1407. doi: 10.3390/v12121407. PMID: 33302389; PMCID: PMC7762593.
11: Hsieh YH, Dugas AF, LoVecchio F, McBryde B, Ricketts EP, Saliba-Shaw K, Rothman RE. Intravenous peramivir vs oral oseltamivir in high-risk emergency department patients with influenza: Results from a pilot randomized controlled study. Influenza Other Respir Viruses. 2021 Jan;15(1):121-131. doi: 10.1111/irv.12794. Epub 2020 Oct 2. PMID: 33006445; PMCID: PMC7767951.
12: Ding H, Wu S, Dai X, Gao Y, Niu Y, Fang N, Song Y, Zhang M, Wang X, Chen T, Zhang G, Wu J, Li Y, Han J. Pharmacokinetic behavior of peramivir in the plasma and lungs of rats after trans-nasal aerosol inhalation and intravenous injection. Biomed Pharmacother. 2020 Sep;129:110464. doi: 10.1016/j.biopha.2020.110464. Epub 2020 Jul 11. PMID: 32768954.
13: Kato M, Saisho Y, Tanaka H, Bando T. Effect of peramivir on respiratory symptom improvement in patients with influenza virus infection and pre-existing chronic respiratory disease: Findings of a randomized, open-label study. Influenza Other Respir Viruses. 2021 Jan;15(1):132-141. doi: 10.1111/irv.12788. Epub 2020 Jul 17. PMID: 32677375; PMCID: PMC7767948.
14: Harada N, Shibata W, Koh H, Takashita E, Fujisaki S, Okamura H, Nanno S, Yamada K, Nakamae H, Hino M, Kakeya H. Successful treatment with baloxavir marboxil of a patient with peramivir-resistant influenza A/H3N2 with a dual E119D/R292K substitution after allogeneic hematopoietic cell transplantation: a case report. BMC Infect Dis. 2020 Jul 6;20(1):478. doi: 10.1186/s12879-020-05205-1. PMID: 32631240; PMCID: PMC7339380.
15: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. Peramivir. 2020 Jun 22. PMID: 31643183.
16: Lee JS, Lee MS, Park Y, Lee J, Joo EJ, Eom JS. Clinical Effectiveness of Intravenous Peramivir versus Oseltamivir for the Treatment of Influenza in Hospitalized Patients. Infect Drug Resist. 2020 May 19;13:1479-1484. doi: 10.2147/IDR.S247421. PMID: 32547116; PMCID: PMC7245436.
17: Takashita E, Yasui Y, Nagata S, Morita H, Fujisaki S, Miura H, Shirakura M, Kishida N, Nakamura K, Kuwahara T, Sugawara H, Sato A, Akimoto M, Kaido T, Watanabe S, Hasegawa H; Influenza Virus Surveillance Group of Japan. Detection of a Peramivir-Resistant Influenza B/Yamagata-Lineage Virus Imported from Indonesia in Aichi, Japan, March 2019. Jpn J Infect Dis. 2020 Sep 24;73(5):386-390. doi: 10.7883/yoken.JJID.2020.084. Epub 2020 May 29. PMID: 32475875.
18: Yoshimura Y, Sasaki H, Horiuchi H, Miyata N, Kawakami C, Usuku S, Tachikawa N. Early combination treatment with baloxavir and peramivir for hospitalized adults with influenza A in Yokohama, Japan. Eur J Clin Microbiol Infect Dis. 2020 Sep;39(9):1637-1640. doi: 10.1007/s10096-020-03888-7. Epub 2020 Apr 14. PMID: 32291543.
19: Chen JY, Wei SK, Lai CC, Weng TS, Wang HH. A Meta-Analysis Comparing the Efficacy and Safety of Peramivir with Other Neuraminidase Inhibitors for Influenza Treatment. Medicina (Kaunas). 2020 Feb 5;56(2):63. doi: 10.3390/medicina56020063. PMID: 32033501; PMCID: PMC7073584.
20: Witcher R, Tracy J, Santos L, Chopra A. Outcomes and Adverse Effects With Peramivir for the Treatment of Influenza H1N1 in Critically Ill Pediatric Patients. J Pediatr Pharmacol Ther. 2019 Nov-Dec;24(6):497-503. doi: 10.5863/1551-6776-24.6.497. PMID: 31719811; PMCID: PMC6836703.
